Author:
Miles Dale,Jumbe Nelson L.,Lacy Steven,Nguyen Linh
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference17 articles.
1. Food and Drug Administration. COMETRIQ (cabozantinib) prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf . Accessed 4 June 2015.
2. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308.
3. Capp C, Wajner SM, Siqueira DR, et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2 in medullary thyroid carcinoma. Thyroid. 2010;20(8):863–71.
4. Cassinelli G, Favini E, Degl’Innocenti D, et al. RET/PTC1-driven neoplastic transformation and proinvasion phenotype of human thyrocytes involve MET induction and beta-catenin nuclear translocation. Neoplasia. 2009;11(1):10–21.
5. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284–90.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献